Exogenous IFN-α therapy or CpG ODN intervention, especially when administered late, has been linked to prolonged hospitalization, and improper or delayed IFN-α treatment in viral infections can lead to hyper-inflammation and worsen outcomes, especially in older adults or individuals with high viral exposure [17]. This evidence concerns the gene IFNA1 and viral infectious disease.